ATRO · Astronics Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ATRO. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ATRO · Astronics Corporation
Astronics Corporation, through its subsidiaries, designs and manufactures products for the aerospace, defense, and electronics industries in the United States, rest of North America, Asia, Europe, South America, and internationally. It operates in two segments, Aerospace and Test Systems. The Aerospace segment offers lighting and safety systems, electrical power generation systems, distribution and seat motions systems, aircraft structures, avionics products, systems certification, and other products. This segment serves airframe manufacturers (OEM) that build aircraft for the commercial transport, military, and general aviation markets; suppliers to OEMs; and aircraft operators, such as airlines; suppliers to the aircraft operators; and branches of the U.S. Department of Defense. The Test Systems segment designs, develops, manufactures, and maintains automated test systems that support the aerospace and defense, communications, and mass transit industries, as well as training and simulation devices for commercial and military applications. This segment serves OEMs and prime government contractors for electronics and military products. The company was incorporated in 1968 and is headquartered in East Aurora, New York.
Live Quote
BUY (score +7) · 12-1 mom 139.3% · RSI 73.6 · above_both · 0.0% from high
Targets blend Wall Street consensus (5 analysts: low $45.73 / mean $76.15 / high $89.17) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Rich valuation (~28x Fwd P/E) and elevated leverage mean the commercial recovery and IFEC tailwinds are already fully priced in. With no insider buying, bearish options skew, and anti-signals for concentration/dilution, there is no clear mispricing or income structure edge at current levels.
Rich valuation (~28x Fwd P/E) and elevated leverage mean the commercial recovery and IFEC tailwinds are already fully priced in. With no insider buying, bearish options skew, and anti-signals for concentration/dilution, there is no clear mispricing or income structure edge at current levels.
Astronics is a well-run aerospace & defense technology company with record Q1 bookings ($290M), backlog of $734M, and strong margin expansion. The stock has surged 170% over 12 months on commercial aerospace recovery and IFEC momentum, but now trades at ~28x forward earnings — rich relative to its peer group. No open-market insider buys were detected (recent Form 4s reflect RSU vestings, not director purchases). Options skew is modestly put-heavy. The company has elevated debt (D/E 234%) and a Lufthansa Technik patent litigation overhang. This is a quality business at full-to-rich valuation with no clear near-term mispricing — the appropriate verdict is structured income on pullbacks rather than an asymmetric long setup.
{"symbol":"ATRO","company":"Astronics Corporation","investigation_summary":"Astronics is a well-run aerospace & defense electronics manufacturer that just reported blowout Q1 FY2026 results — 12% revenue growth, record bookings of $290M, and a backlog of $734M (new company records). The stock has run +49% YTD and sits ~2.8% from its 52-week high. However, the shares trade at 28x forward earnings w
The dossier flags convertible dilution risk (>$10M float overhang) and high leverage (5.3x net debt/EBITDA) alongside a lack of mispricing near a 52-week high. With no insider buying, material insider selling, and no asymmetric catalyst, the risk/reward profile fails to clear the publication threshold.
Astronics is a well-run aerospace & defense supplier with strong earnings momentum (four consecutive EPS beats) and accelerating revenue growth (+12% YoY in Q1 2026). However, the stock has already run ~114% over one year and sits just 7% below its 52-week high at $78.26. The May 12, 2026 8-K revealed a Q1 beat (EPS $0.59 vs $0.56 est; revenue $230.6M) yet the stock dropped — suggesting the market is already paying close attention and may be fully valuing near-term prospects. Forward P/E of ~25x with EV/EBITDA of ~26.5x leaves modest upside to consensus target ($86.58). The only actionable thesis here is a covered-call or strangle income strategy on a high-IV aerospace name at/near its peak.